UBS Group
BIS icon

UBS Group’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

UBS Group’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9 Hold
1
– – ﹤0.01% 10340
2025
Q4 		$9 Hold
1
– – ﹤0.01% 10386
2025
Q3 		$13 Sell
1
-108
-99% -$3.22K ﹤0.01% 10168
2025
Q2 		$3.86K Buy
109
+108
+10,800% +$4.13K ﹤0.01% 9313
2025
Q1 		$19 Hold
1
– – ﹤0.01% 10094
2024
Q4 		$18 Hold
1
– – ﹤0.01% 9778
2024
Q3 		$15 Hold
1
– – ﹤0.01% 9332
2024
Q2 		$17 Sell
1
-6
-86% -$218 ﹤0.01% 9320
2024
Q1 		$247 Sell
7
-130
-95% -$4.59K ﹤0.01% 8689
2023
Q4 		$4.93K Buy
137
+134
+4,467% +$6.11K ﹤0.01% 7813
2023
Q3 		$134 Sell
3
-542
-99% -$22.8K ﹤0.01% 8811
2023
Q2 		$22.7K Sell
545
-1,267
-70% -$50.3K ﹤0.01% 6816
2023
Q1 		$73.5K Buy
1,812
+630
+53% +$25.1K ﹤0.01% 6152
2022
Q4 		$46.4K Buy
1,182
+1,181
+118,100% +$49.2K ﹤0.01% 6838
2022
Q3 		$0 Sell
1
-200
-100% -$9.47K ﹤0.01% 10335
2022
Q2 		$11K Sell
201
-485
-71% -$27.1K ﹤0.01% 7784
2022
Q1 		$33K Buy
686
+243
+55% +$12.4K ﹤0.01% 6898
2021
Q4 		$18K Sell
443
-1,070
-71% -$41.9K ﹤0.01% 7963
2021
Q3 		$55K Buy
1,513
+803
+113% +$28K ﹤0.01% 6260
2021
Q2 		$26K Buy
710
+709
+70,900% +$30.1K ﹤0.01% 7066
2021
Q1 		$0 Sell
1
-2,340
-100% -$98.3K ﹤0.01% 9000
2020
Q4 		$110K Buy
+2,341
New +$128K ﹤0.01% 5628
2020
Q2 		– Sell
-61
Closed -$7K – 7941
2020
Q1 		$7K Sell
61
-186
-75% -$21.2K ﹤0.01% 7130
2019
Q4 		$26K Sell
247
-49
-17% -$6.3K ﹤0.01% 6723
2019
Q3 		$47K Buy
296
+206
+229% +$30.2K ﹤0.01% 6233
2019
Q2 		$12K Sell
90
-192
-68% -$28.1K ﹤0.01% 6935
2019
Q1 		$38K Sell
282
-139
-33% -$19.6K ﹤0.01% 5751
2018
Q4 		$78K Buy
421
+117
+38% +$18.9K ﹤0.01% 5747
2018
Q3 		$38K Buy
+304
New +$40.9K ﹤0.01% 6368
2018
Q2 		– Sell
-401
Closed -$68K – 7976
2018
Q1 		$68K Buy
401
+339
+547% +$54.4K ﹤0.01% 5491
2017
Q4 		$11K Sell
62
-339
-85% -$60.2K ﹤0.01% 6946
2017
Q3 		$66K Buy
401
+78
+24% +$14.1K ﹤0.01% 5602
2017
Q2 		$63K Buy
+323
New +$70.4K ﹤0.01% 5494
2017
Q1 		– Sell
-224
Closed -$63K – 7635
2016
Q4 		$63K Buy
+224
New +$61.3K ﹤0.01% 5642
2016
Q3 		– Sell
-205
Closed -$68K – 7673
2016
Q2 		$68K Buy
205
+77
+60% +$24.3K ﹤0.01% 5288
2016
Q1 		$45K Sell
128
-274
-68% -$95.3K ﹤0.01% 5585
2015
Q4 		$92K Buy
402
+18
+5% +$4.63K ﹤0.01% 5281
2015
Q3 		$118K Buy
384
+172
+81% +$40.6K ﹤0.01% 5082
2015
Q2 		$49K Buy
+212
New +$52.6K ﹤0.01% 6018
2015
Q1 		– Sell
-42
Closed -$16K – 8819
2014
Q4 		$16K Buy
+42
New +$17.5K ﹤0.01% 7945

Other funds holding BIS

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group's BIS Position: Q1 2026 in Review

UBS Group held its ProShares UltraShort NASDAQ Biotechnology (BIS) position steady in Q1 2026 at 1 share worth $9. The position accounts for ﹤0.01% of the portfolio, ranked #10340.

UBS Group first reported a position in BIS in Q4 2014 and has held it in 40 quarters since. The position peaked at $118K in Q3 2015. 4 funds tracked by Wall St. Rank hold BIS as of Q1 2026.

  • UBS Group held 1 share of ProShares UltraShort NASDAQ Biotechnology worth $9 as of Q1 2026.
  • UBS Group left its ProShares UltraShort NASDAQ Biotechnology share count unchanged in Q1 2026.
  • ProShares UltraShort NASDAQ Biotechnology made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10340 holding.
  • UBS Group first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q4 2014 and has held it in 40 quarters since.
  • UBS Group's ProShares UltraShort NASDAQ Biotechnology position peaked at $118K in Q3 2015.
  • 4 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.